3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
79
Lung Neoplasms
44
Carcinoma, Hepatocellular
43
Small Cell Lung Carcinoma
28
Breast Neoplasms
19
Cholangiocarcinoma
17
Urinary Bladder Neoplasms
16
Biliary Tract Neoplasms
15
Neoplasms
13
Liver Neoplasms
13
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
11
Ovarian Neoplasms
10
Carcinoma
10
Squamous Cell Carcinoma of Head and Neck
8
Stomach Neoplasms
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Transitional Cell
6
Melanoma
5
Gallbladder Neoplasms
5
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Prostatic Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Mesothelioma
4
Interventions
Cisplatin
3
Radiotherapy, Intensity-Modulated
2
pembrolizumab
1
palbociclib
1
durvalumab
1
Taxes
1
Pemetrexed
1
Paclitaxel
1
Nimorazole
1
Immunotherapy
1
Cell Count
1
Carboplatin
1
Bevacizumab
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
durvalumab
×
1 year
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled